Mechanisms of Efficacy of the PAN-FGFR Inhibitor AZD4547 in Pediatric Solid Tumor Models

被引：0
|
作者：
Zage, P. [1 ]
Hakim, S. [1 ]
Subramonian, D. [1 ]
Lesperance, J. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, Pediat, San Diego, CA 92103 USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-052
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 50 条
  • [21] Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin
    Heroult, Melanie
    Ocker, Matthias
    Kopitz, Charlotte
    Zopf, Dieter
    Haegebarth, Andrea
    Ziegelbauer, Karl
    Ince, Stuart
    Ellinghaus, Peter
    CANCER RESEARCH, 2015, 75
  • [22] Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Kilgour, Elaine
    Ferry, David
    Saggese, Matilde
    Arkenau, Hendrik-Tobias
    Rooney, Claire
    Smith, Neil R.
    Baker, Dawn
    Dougherty, Brian
    Womack, Chris
    Smith, Paul D.
    Ghiorghiu, Dana C.
    Harrington, Elizabeth A.
    Barrett, J. Carl
    Brooks, Nigel
    Stockman, Paul
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
    Liang, Donglou
    Chen, Qiaowan
    Guo, Yujin
    Zhang, Ting
    Guo, Wentao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 451 - 461
  • [24] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Qingxia Zhao
    Amanda B. Parris
    Erin W. Howard
    Ming Zhao
    Zhikun Ma
    Zhiying Guo
    Ying Xing
    Xiaohe Yang
    Scientific Reports, 7
  • [25] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Zhao, Qingxia
    Parris, Amanda B.
    Howard, Erin W.
    Zhao, Ming
    Xing, Ying
    Ma, Zhikun
    Yang, Xiaohe
    CANCER RESEARCH, 2017, 77
  • [26] FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial-mesenchymal transition to gefitinib
    Luo, Hong
    Quan, Jin
    Xiao, He
    Luo, Jia
    Zhang, Qin
    Pi, Guocheng
    Ye, Yunfei
    He, Rong
    Liu, Yun
    Su, Xiaona
    Zhao, Lianhua
    Wang, Ge
    ONCOLOGY REPORTS, 2018, 39 (05) : 2270 - 2278
  • [27] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Zhao, Qingxia
    Parris, Amanda B.
    Howard, Erin W.
    Zhao, Ming
    Ma, Zhikun
    Guo, Zhiying
    Xing, Ying
    Yang, Xiaohe
    SCIENTIFIC REPORTS, 2017, 7
  • [28] The resistance mechanism of FGFR2 amplified gastric cancer cells against AZD4547, a fibroblast growth factor receptor inhibitor
    Lee, S. Y.
    Jeong, Y.
    Na, Y.
    Kim, J. L.
    Lee, D. H.
    Oh, S. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (vol 13, 3246, 2022)
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I.
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Ferguson, V.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [30] Selective FGFR inhibitor, AZD4547, modulates bone microenvironment by suppressing RNAKL/M-CSF/Osteocalcine induced osteoclastogenesis in FGFR-amplified breast cancer
    Choi, Y. J.
    Kang, J.
    Lee, H. J.
    Jo, U.
    Park, S. I.
    Bae, J. W.
    Park, K. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S118 - S119
12345